We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 3.45% | 150.00 | 140.00 | 160.00 | 150.00 | 150.00 | 150.00 | 1,565 | 08:00:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -3.59 | 103.18M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/12/2018 08:37 | Loads of buys coming through now | rakepat37 | |
05/12/2018 08:17 | If we were at 10 pounds then we would be at 15 a share , can't believed we are at 82p , this is going to be massive | rakepat37 | |
05/12/2018 08:10 | Spread is tight which is great for traders, we should blow £ 1 | rakepat37 | |
05/12/2018 08:04 | Fascinating stuff, I wonder if there are any other real world consequences for the circa 40% of individuals with the mutation? I assume that those of us with the mutation are walking around blissfully unaware that we have it, or does the mutation manifest its self in other ways? Given that Interferon is also used to treat MS and COPD exacerbations (Synairgen), I cannot help wondering whether this relatively common mutation is going to have an influence in outcomes for those two indications when treated with interferon. Any thoughts? | timbo003 | |
05/12/2018 07:17 | Great RNS this will have to rerate soon as the potential is massive | rakepat37 | |
05/12/2018 05:57 | ARDS is rare and there is no drug treatment for it. | troajan1 | |
03/12/2018 11:14 | Saw a yellow 'Bitcoin Van' In Rochester yesterday. Maybe that where he is hiding. | jobber1 | |
28/11/2018 13:23 | So why is it this price?? | ic0gcds00 | |
27/11/2018 08:13 | Looks like we are also in yesterday medical news - Global Acute Lung Injury Market 2018 GSK, Altor BioScience Corp, Faron Pharmaceuticals Oy, Altor BioScience CorpBY NICOLEAUSTIN ON NOVEMBER 26, 2018 | rakepat37 | |
22/11/2018 09:04 | Seriously under valued share, only 20mil shares in issue, this will move fast on incoming news which looks imminent. | rakepat37 | |
09/11/2018 14:58 | For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10. | spmc | |
06/11/2018 17:06 | Confidence boost with yet more Director buys.... DL | davidlloyd | |
29/10/2018 12:03 | Anybody in this should look at DIURNAL/DNL Drugs for leukaemia and cancer accepted for use in Scotland HTTP ://wilmingtonhealthc | troajan1 | |
24/10/2018 17:07 | any directors buying | latifs100 | |
24/10/2018 15:48 | Being offered 68p to sell | herb clark | |
24/10/2018 15:29 | Why did they have to come out with that rns, | ic0gcds00 | |
24/10/2018 14:39 | F u ck me that's a double black diamond ski slope chart for the month. Pharma stocks are mad. Bailed it at about 107p ages ago before it jumped way higher.Look at DEST. CMS in at double the price. Looking for at least 130p there. | mikeh30 | |
23/10/2018 22:05 | Looking at some of the larger trades today I think the mm's are playing us like a fiddle. Hopefully an interview with Proactive will clear things up, and put a more positive spin on the share price | dan1nat1 | |
23/10/2018 18:34 | No money? Farn are funded for 12 months. There could be a farm in for Clevergen before any further money is needed. And we will have Jap results and Yoda results in the next 8-9 weeks, which should significantly boost the share price if positive. There is little chance of a cash call at these levels. | dan1nat1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions